By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Quark Pharmaceuticals Inc. 

6501 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-402-4020 Fax: 510-402-4021


SEARCH JOBS








Company News
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014 6:31:05 AM
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014 10:34:03 AM
Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients 7/1/2014 9:02:30 AM
Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma 6/25/2014 9:15:28 AM
Quark Pharmaceuticals Inc. And Suzhou Ribo Life Science Raise Nearly RMB 45 Million For Newly Established Chinese Joint Venture 1/7/2014 9:33:17 AM
Silence Therapeutics plc' Partner, Quark Pharmaceuticals Inc., Extends its Agreement With Pfizer Inc. (PFE) to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5/3/2012 7:02:19 AM
Quark Pharmaceuticals Inc. Announces Phase 2a Study of PF--04523655 (PF-655) in Patients With Moderate and Advanced Open-Angle Glaucoma (OAG) 5/1/2012 10:16:34 AM
Quark Pharmaceuticals Inc. Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) 1/4/2012 10:33:13 AM
Regarding Announcement of Quark Pharmaceuticals Inc. 3/23/2011 10:18:42 AM
Silence Therapeutics plc Partner Quark Pharmaceuticals Inc. Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema 3/21/2011 9:38:51 AM
12345
//-->